Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
/in International Publications, Newcastle Disease Virus /von 2014-03-07 / Immunol. Lett. 2014 May-Jun;159(1-2):36-46Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2014-03-05 / Sci Transl Med 2014 Mar;6(226):226ra32Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
/in International Publications, Newcastle Disease Virus /von 2014-01-06 / Oncoimmunology 2014 Jan;3(1):e27622Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-30Oncolytic viruses as therapeutic cancer vaccines
/in International Publications, Newcastle Disease Virus /von 2013-09-11 / Mol. Cancer 2013 Sep;12(1):103TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro
/in International Publications, Newcastle Disease Virus /von 2013-08-19 / Anat Rec (Hoboken) 2013 Oct;296(10):1552-60Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75Role of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL.
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution